Efficacy in Subgroups Related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
September 2023
in “
Journal of the American Academy of Dermatology
”
TLDR Baricitinib significantly improves hair regrowth in severe alopecia areata.
The study titled "44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2" evaluated the efficacy of baricitinib, an oral JAK1/JAK2 inhibitor, in treating adults with severe alopecia areata (AA). The results from the BRAVE-AA1 and BRAVE-AA2 trials demonstrated that baricitinib significantly improved hair regrowth in patients with AA, regardless of disease characteristics. The trials included a substantial number of participants, providing robust evidence for the effectiveness of baricitinib in this patient population. These findings support the use of baricitinib as a treatment option for severe AA in the US, Europe, and Japan.